Wednesday October 28th, 2026
The pharmaceutical industry has long enjoyed a peculiar privilege: It can produce something the world desperately wants and charge accordingly. Governments, however, have developed their own ideas about what medicine should cost. This Thursday, Eli Lilly and Merck will offer two perspectives on the consequences. Lilly is selling substantially more medicine while collecting less for each unit sold. Merck faces a different predicament. Keytruda, the cancer treatment that accounted for nearly half its sales last year, is approaching the day when government price negotiations and biosimilar competition will challenge its extraordinary profitability. One company must prove that volume can overcome falling prices. The other must demonstrate that innovation can drive revenue.
The distinction is important because pharmaceutical growth is increasingly becoming a question of arithmetic rather than pricing power. Lilly’s second-quarter revenue rose 48% as volume increased 60%, while realized prices declined 13%. Merck, meanwhile, is preparing for the consequences of government pricing decisions that could materially reduce sales of its most important product. Both companies report Thursday morning. We established our Bull and Bear lines on October 25, before either company reported, and we’re publishing them now. The purpose is straightforward: Management may revise its forecasts, investors may revise their expectations, and Wall Street may revise its explanations, we won’t revise our numbers. The purpose of scorecards is not to prove that we can see the future. It is to prevent ourselves from rewriting the past.
Eli Lilly (reports Thursday, October 29; call at 10:00 a.m. ET)
Bull Case
Third-quarter revenue: At or above $22.97B (no lower than the second quarter).
Full-year revenue guidance: Raised above $87.0B (current range $85.0–87.0B).
Full-year non-GAAP EPS guidance: Raised above $36.50 (current range $35.50–36.50).
Full-year performance margin guidance: Raised above 50.5% (current range 49.0–50.5%).
Bear Case
Third-quarter revenue: Below $21.11B (the pace the bottom of guidance requires; our arithmetic).
Revenue guidance: Cut below $85.0B.
EPS guidance: Cut below $35.50.
Margin guidance: Cut below 49.0%.
Why This Release Matters
Lilly’s second-quarter revenue rose 48% to $22.97 billion. Volume rose 60%, while realized prices fell 13%; outside the U.S., prices fell 36%, mainly because China added Mounjaro to its national reimbursement list. Guidance implies $21.1 to $22.1 billion a quarter for the rest of the year, below a second quarter that included a $250 million milestone payment.
Merck (reports Thursday, October 29; call at 9:00 a.m. ET)
Bull Case
Third-quarter sales: At or above $17.20B.
Third-quarter non-GAAP EPS: At or above $2.15.
Keytruda sales, including Keytruda Qlex: At or above $8.50B.
Keytruda Qlex (under-the-skin): At or above $600M.
Winrevair: At or above $700M.
Bear Case
Third-quarter sales: Below $16.70B (the pace the bottom of guidance requires; our arithmetic).
Third-quarter non-GAAP EPS: Below $2.04.
Keytruda sales, including Qlex: Below $8.14B (less than a year ago).
Keytruda Qlex: At or below $463M (no growth from the second quarter).
Winrevair: At or below $588M.
Why This Release Matters
Keytruda was 49% of Merck’s 2025 sales. Merck’s annual report says biosimilar competition could begin in December 2028, and it expects Keytruda to be chosen for government price setting effective January 1, 2029, after which U.S. sales “will decline materially.” In the second quarter, intravenous Keytruda fell 1% to $7.90 billion, and Qlex added $463 million. Two acquisition charges, $9.0 billion for Cidara and $5.7 billion for Terns, left a first-half non-GAAP loss of $1.41 a share, yet full-year guidance is $2.66 to $2.76. The second half has to deliver about $4.07 to $4.17 a share (our arithmetic).
What Two Drugmakers Say About the Economy
Where does a drugmaker’s growth come from when prices are under pressure?
Lilly’s growth now comes almost entirely from volume: more patients, at lower prices, in more countries. That widens access and tests margins, which is why we track the performance margin too.
Merck shows the other side. Under the Inflation Reduction Act, Medicare now sets prices for some of the drugs it spends the most on, and Merck has written the effect on its largest product into its own risk disclosures. Qlex and Winrevair show how fast it can replace that revenue.
The price of medicine is being set less by list-price increases and more by volume, national formularies and Washington. If that holds, drug spending grows because more people are treated, not because each treatment costs more.
We will grade Lilly and Merck against these lines after they report. Lines first, results second, misses included.
Subscribe to Portfolio Lens Research and get the scorecard when it lands.
For information only. Not investment advice. Nothing in this article is a recommendation to buy, sell or hold any security.
Sources: Lilly Q2 2026 release (8-K, Aug 5, 2026) · Lilly Q1 2026 release (8-K, Apr 30, 2026) · Lilly Q3 2026 call date · Merck Q2 2026 release (8-K, Aug 4, 2026) · Merck Q3 2025 release (8-K, Oct 30, 2025) · Merck 2025 Form 10-K · Merck Q3 2026 call date


